Has the Time Come to Revisit Our Standard Measures of Disability Progression in Multiple Sclerosis?
暂无分享,去创建一个
[1] B. Uitdehaag,et al. Reliability of Outcome Measures in Clinical Trials in Secondary Progressive Multiple Sclerosis , 2020, Neurology.
[2] C. Stadelmann,et al. Remyelination in multiple sclerosis: from basic science to clinical translation , 2020, The Lancet Neurology.
[3] M. Trojano,et al. Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis. , 2020, JAMA neurology.
[4] L Nab,et al. Measurement error in continuous endpoints in randomised trials: Problems and solutions , 2018, Statistics in medicine.
[5] D. Arnold,et al. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension , 2018, The Lancet Neurology.
[6] Frederik Barkhof,et al. Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting , 2018, Nature Reviews Neurology.
[7] Jeffrey A. Cohen,et al. Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function , 2017, The Lancet.
[8] Bernhard Hemmer,et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis , 2017, The New England journal of medicine.
[9] Derek K. Jones,et al. Neuroplasticity and functional recovery in multiple sclerosis , 2012, Nature Reviews Neurology.